Henry Tran, MD
Cardiovascular Disease · Falls Church, VANPI 1689895153
Payments from drug & device makers
Across 593 payments — averaging $2682.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$489K
- Novo Nordisk AS$453K
- Ortho-clinical Diagnostics, Inc.$417K
- Amgen$91K
- Bayer$57K
- Siemens Medical Solutions USA, Inc.$39K
- plus $45K from 28 others
Across 3 payments — averaging $9816.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ortho-clinical Diagnostics, Inc.$29K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 26 | $489,330 |
| Novo Nordisk AS | 460 | $453,265 |
| Ortho-clinical Diagnostics, Inc. | 7 | $417,369 |
| Amgen | 12 | $90,683 |
| Bayer | 17 | $56,776 |
| Siemens Medical Solutions USA, Inc. | 3 | $38,647 |
| E.r. Squibb & Sons, L.L.C. | 14 | $21,697 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $11,400 |
| Boehringer Ingelheim International GmbH | 2 | $10,020 |
| Abbott | 3 | $462 |
| Lilly USA, LLC | 7 | $142 |
| Medtronic(2 entities) | 4 | $140 |
| Novo Nordisk | 1 | $115 |
| Johnson & Johnson | 4 | $92 |
| AbbVie | 3 | $84 |
| Eisai Inc. | 3 | $65 |
| Bardy Diagnostics, Inc. | 3 | $62 |
| Alnylam Pharmaceuticals Inc. | 1 | $57 |
| Boston Scientific | 2 | $48 |
| UCB, Inc. | 2 | $43 |
| Boehringer Ingelheim | 2 | $41 |
| Pfizer | 2 | $37 |
| Genentech USA, Inc. | 2 | $37 |
| Philips North America LLC | 1 | $30 |
| Cvrx, Inc. | 1 | $27 |
| Amneal Pharmaceuticals LLC | 1 | $26 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Acorda Therapeutics, Inc | 1 | $22 |
| Neurelis, Inc. | 1 | $20 |
| Corium, LLC | 2 | $20 |
| Biogen | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| CSL Behring | 1 | $15 |
How this compares
$1,590,845 in reported general payments places this provider in the 95th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Falls Church
- Tariq HaddadFalls Church$8M
- Behnam TehraniFalls Church$514K
- Mitchell PsotkaFalls Church$246K
- Shashank SinhaFalls Church$235K
- Alexander TruesdellFalls Church$176K
- Christopher OconnorFalls Church$161K
- Joseph KreppFalls Church$157K
- David LimCharlottesville$6M
- Hamid TaheriManassas$4.9M
- Philip OdonnellWinchester$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.